Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
36.91
-0.61 (-1.63%)
At close: Oct 30, 2026, 4:00 PM EDT
37.00
+0.09 (0.24%)
After-hours: Oct 30, 2026, 7:53 PM EDT
Roivant Sciences Revenue
Roivant Sciences had revenue of $1.44M in the quarter ending June 30, 2026, a decrease of -33.55%. This brings the company's total for the last twelve months to $7.53M, down -67.58% year-over-year. In the fiscal year ending March 31, 2026, Roivant Sciences had annual revenue of $8.26M, down -71.57%. That makes Roivant Sciences the 38,540th largest company in the world by revenue and 5,071st in the United States.
Revenue (ttm)
$7.53M
Revenue Growth
-67.58%
P/S Ratio
3,539.69
Revenue / Employee
$10,447
Employees
721
Market Cap
26.66B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.26M | -20.79M | -71.57% |
| Mar 31, 2025 | 29.05M | -3.66M | -11.19% |
| Mar 31, 2024 | 32.71M | -28.57M | -46.62% |
| Mar 31, 2023 | 61.28M | 5.99M | 10.84% |
| Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
| Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
| Mar 31, 2020 | 67.69M | 65.37M | 2,812.61% |
| Mar 31, 2019 | 2.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.13B |
| Incyte | 6.01B |
| Alnylam Pharmaceuticals | 5.01B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Exelixis | 2.44B |
| Halozyme Therapeutics | 1.66B |
ROIV News
- 4 days ago - Roivant Sciences price target raised to $56 from $46 at Citi - TheFly
- 10 days ago - Roivant Sciences price target raised to $62 from $55 at TD Cowen - TheFly
- 11 days ago - Roivant Sciences Transcript: Study result - Transcripts
- 11 days ago - Roivant Sciences Press release: Study result - Filings
- 11 days ago - Roivant Sciences Slides: Study result - Filings
- 11 days ago - Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) - GlobeNewsWire
- 11 days ago - Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 - GlobeNewsWire
- 19 days ago - Citi opens ‘upside 90-day catalyst watch’ on Roivant Sciences - TheFly